Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C - a randomized trial

Table 6 Groups of weight loss and liver function parameters in patients with NGLCD

		Weight gain		1-5% weight loss		5-10% weight loss		Weight loss >10%		p
		Mean	SD	Mean	SD	Mean	SD	Mean	SD
PA (min/week)	Baseline	17.0	3.9	27.5	16.2	34.4	23.6	28.7	20.8	0.310
	12-months	46.0	21.0	74.1	39.7	106.2	40.7	114.5	26.6	0.002
Weight (kg)	Baseline	85.4	15.0	85.8	15.1	82.9	11.1	77.9	6.7	0.592
	12-months	86.5	14.5	83.6	14.7	76.4	10.7	67.7	6.2	0.024
BMI (kg/m²)	Baseline	28.7	3.8	29.6	3.1	30.4	4.6	27.2	0.8	0.295
	12-months	29.1	3.6	28.9	3.0	28.0	4.5	23.6	0.6	0.011
AST (IU/l)	Baseline	44.8	25.0	51.8	31.7	61.8	45.2	32.3	16.9	0.336
	12-months	35.1	17.9	46.3	22.4	51.9	36.4	35.7	12.5	0.460
ALT (IU/l)	Baseline	41.5	24.9	68.7	42.0	61.3	44.9	35.2	26.7	0.213
	12-months	31.5	14.5	53.6	28.0	54.9	31.4	34.2	19.2	0.168
Albumin (g/dl)	Baseline	4.4	0.5	4.3	0.3	4.2	0.4	4.4	0.3	0.430
	12-months	4.3	0.3	4.4	0.4	4.4	0.4	4.5	0.2	0.744
Bi (g/dl)	Baseline	0.6	0.3	0.7	0.2	0.6	0.2	0.6	0.1	0.566
	12-months	0.6	0.3	0.6	0.2	0.6	0.2	0.6	0.1	0.653
GGT (IU/l)	Baseline	36.4	23.7	58.4	31.1	59.4	47.8	39.3	26.1	0.403
	12-months	30.8	19.2	51.9	34.2	46.9	29.3	24.3	8.0	0.152
AST/ALT	Baseline	1.2	0.4	0.8	0.3	1.1	0.5	1.1	0.5	0.050
	12-months	1.1	0.2	0.9	0.2	1.0	0.3	1.2	0.5	0.075
FI	Baseline	5.5	0.7	5.8	1.2	5.6	1.2	4.6	0.5	0.160
	12-months	5.3	0.5	5.6	1.1	5.4	1.3	4.3	0.5	0.086
APRI	Baseline	0.6	0.4	0.7	0.5	0.9	0.8	0.4	0.2	0.419
	12-months	0.5	0.3	0.6	0.4	0.7	0.6	0.4	0.2	0.596

NGLCD normoglucidic low-calorie diet, PA physical activity, BMI body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, Bi bilirubin, GGT gamma-glutamyl transpeptidase, AST/ALT aspartate aminotransferase/alanine aminotransferase ratio, FI Forns fibrosis index, APRI AST to platelet ratio index.

ISSN: 1475-2891